journal article·2026-06Open access

“Artificial platelet injection system”: a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation

Chenming Zou, Haichao Zhu, Yuepeng Tang, Shengrong Guo

Abstract

Targeted protein degradation technology via lysosomal machinery has attracted extensive attention due to its capability of degrading extracellular and membrane-associated proteins. Conventional lysosome-based degraders are established by conjugating bifunctional chimaeras, which requires complex multi-step synthesis and time-consuming purification. Isolated activated platelets have been found to target and be engulfed by tumor cells, raising the possibility of being harnessed for intracellular payload injection. Here, inspired by injection systems of endosymbiotic bacteria and bacteriophages, we develop an "artificial platelet injection system", a plug-and-play platelet-based lysosome-targeting chimera (PLT-TAC) via a facile microfluidic approach. PLT-TACs are meticulously manufactured by anchoring protein ligands and lysosome-sorting signal peptides onto activated platelet membrane, and can be easily optimized by tuning the peptide ratio on platelets to pursue the efficient protein degradation. Once PLT-TACs adhere to the tumor cytomembrane, they can be internalized into cells, and lysosome-sorting peptides initiate the "injection" of targeted proteins into lysosomes, thereby promoting the lysosomal degradation process. To test our concept, we use a peptide ligand targeting the immune checkpoint PD-L1 to engineer PLT-TACs. Efficient degradation of PD-L1 is confirmed both in vitro and in vivo. Furthermore, PLT-TACs can also degrade other proteins by simply installing alternative ligands. Our study proposes a new autologous cell-based protein degrader, with broad applicability in research and clinical practice.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · Autophagy in Disease and Therapy · HIV Research and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (52)

Show source-provided references
1. Development of targeted protein degradation therapeutics10.1038/s41589-019-0362-y ↗
2. PROTAC targeted protein degraders: the past is prologue10.1038/s41573-021-00371-6 ↗
3. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation10.1073/pnas.141230798 ↗
4. The rise of molecular glues10.1016/j.cell.2020.12.020 ↗
5. A method for the acute and rapid degradation of endogenous proteins10.1016/j.cell.2017.10.033 ↗
6. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
7. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation10.1038/s41589-021-00770-1 ↗
8. Targeted protein degradation in the transmembrane and extracellular space10.1126/science.adx5094 ↗
9. Bifunctional compounds as molecular degraders for Integrin- facilitated targeted protein degradation10.1021/jacs.2c08367 ↗
10. Degradation of lipid droplets by chimeric autophagy-tethering compounds10.1038/s41422-021-00532-7 ↗
11. Programmable protein delivery with a bacterial contractile injection system10.1038/s41586-023-05870-7 ↗
12. In situ architecture, function, and evolution of a contractile injection system10.1126/science.aan7904 ↗
13. Cryo-EM structure and assembly of an extracellular contractile injection system10.1016/j.cell.2019.02.020 ↗
14. A type VI secretion system effector delivery mechanism dependent on PAAR and a chaperone-co-chaperone complex10.1038/s41564-018-0144-4 ↗
15. Type VI secretion requires a dynamic contractile phage tail-like structure10.1038/nature10846 ↗
16. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance10.1016/j.ccell.2023.01.001 ↗
17. Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus10.1016/j.biomaterials.2025.123674 ↗
18. Uptake of platelets by cancer cells and recycling of the platelet protein CD42a10.1111/jth.15543 ↗
19. The dynamic role of platelets in cancer progression and their therapeutic implications10.1038/s41568-023-00639-6 ↗
20. Lysosomal biology and function: modern view of cellular debris bin10.3390/cells9051131 ↗
21. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function10.1038/nrm2745 ↗
22. Covalently engineered nanobody chimeras for targeted membrane protein degradation10.1021/jacs.1c08521 ↗
23. Harnessing the lysosomal sorting signals of the cation-independent Mannose-6-Phosphate receptor for targeted degradation of membrane proteins10.1021/jacs.3c07687 ↗
24. Platelet biology and functions: new concepts and clinical perspectives10.1038/s41569-018-0110-0 ↗
25. Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology10.1038/s41580-023-00676-x ↗
26. Platelet transfusion 2025 AABB and ICTMG international clinical practice guidelines10.1001/jama.2025.7529 ↗
27. How to explain the beneficial effects of platelet-rich plasma10.1111/prd.12565 ↗
28. Engineered platelets for cancer therapy
29. Cell-drug conjugates10.1038/s41551-024-01230-6 ↗
30. Platelet-drug conjugates engineered via one-step fusion approach for metastatic and postoperative cancer treatment
31. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy10.1038/s41551-016-0011 ↗
32. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy10.1038/s41551-018-0310-2 ↗
33. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity10.1038/nature23643 ↗
34. Mutational analysis of the cation-independent mannose 6-phosphate/Insulin-like growth factor II receptor. A consensus casein kinase II site followed by 2 leucines near the carboxyl terminus is important for intracellular targeting of lysosomal enzymes10.1016/S0021-9258(18)41533-5 ↗
35. Systematic mutational analysis of the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain - an acidic cluster containing a key aspartate is important for function in lysosomal enzyme sorting10.1074/jbc.272.11.7003 ↗
36. Recent advances of controlled drug delivery using microfluidic platforms10.1016/j.addr.2017.09.013 ↗
37. Microfluidics for advanced drug delivery systems10.1016/j.coche.2014.12.001 ↗
38. Mechanisms of clathrin-mediated endocytosis10.1038/nrm.2017.132 ↗
39. Mechanics of receptor-mediated endocytosis10.1073/pnas.0503879102 ↗
40. Programming DNA nanoassemblies into polyvalent lysosomal degraders for potent degradation of pathogenic membrane proteins10.1021/acs.nanolett.4c03102 ↗
41. Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy10.1126/sciadv.adq3940 ↗
42. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response10.1038/s41586-018-0392-8 ↗
43. Covalent LYTAC enabled by DNA aptamers for immune checkpoint degradation therapy
44. Robust deep learning-based protein sequence design using ProteinMPNN10.1126/science.add2187 ↗
45. Designed endocytosis-inducing proteins degrade targets and amplify signals10.1038/s41586-024-07948-2 ↗
46. Signals for sorting of transmembrane proteins to endosomes and lysosomes10.1146/annurev.biochem.72.121801.161800 ↗
47. A gene network regulating lysosomal biogenesis and function10.1126/science.1174447 ↗
48. Macrophages recycle phagocytosed bacteria to fuel immunometabolic responses10.1038/s41586-025-08629-4 ↗
49. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
50. Transferrin receptor targeting chimeras for membrane protein degradation10.1038/s41586-024-07947-3 ↗
51. Receptor mediated uptake of peptides that bind the human transferrin receptor10.1046/j.1432-1327.2001.02073.x ↗
52. Targeted protein degradation via cellular trafficking of nanoparticles10.1038/s41565-024-01801-3 ↗